[HTML][HTML] The multifaceted role of plasminogen in inflammation

B Heissig, Y Salama, S Takahashi, T Osada, K Hattori - Cellular signalling, 2020 - Elsevier
A fine-tuned activation and deactivation of proteases and their inhibitors are involved in the
execution of the inflammatory response. The zymogen/proenzyme plasminogen is converted …

[HTML][HTML] The role of the plasminogen/plasmin system in inflammation of the oral cavity

T Yatsenko, M Skrypnyk, O Troyanovska, M Tobita… - Cells, 2023 - mdpi.com
The oral cavity is a unique environment that consists of teeth surrounded by periodontal
tissues, oral mucosae with minor salivary glands, and terminal parts of major salivary glands …

[HTML][HTML] TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR

T Zhang, B Wang, F Su, B Gu, L Xiang… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, and distant
metastasis is a critical factor in the prognosis of patients with GC. Understanding the …

[HTML][HTML] Structural biology and protein engineering of thrombolytics

J Mican, M Toul, D Bednar, J Damborsky - Computational and structural …, 2019 - Elsevier
Myocardial infarction and ischemic stroke are the most frequent causes of death or disability
worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently used …

[HTML][HTML] The multifaceted role of plasminogen in cancer

B Heissig, Y Salama, T Osada, K Okumura… - International Journal of …, 2021 - mdpi.com
Fibrinolytic factors like plasminogen, tissue-type plasminogen activator (tPA), and urokinase
plasminogen activator (uPA) dissolve clots. Though mere extracellular-matrix-degrading …

[HTML][HTML] uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients

L Porcelli, M Guida, S De Summa… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …

Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1

AA Ibrahim, T Fujimura, T Uno, T Terada… - Frontiers in …, 2024 - frontiersin.org
Background Increased levels of plasminogen activator inhibitor-1 (PAI-1) in tumors have
been found to correlate with poor clinical outcomes in patients with cancer. Although …

[HTML][HTML] Plasmin drives burn-induced systemic inflammatory response syndrome

BHY Gibson, CC Wollenman, SN Moore-Lotridge… - JCI insight, 2021 - ncbi.nlm.nih.gov
Severe injuries, such as burns, provoke a systemic inflammatory response syndrome (SIRS)
that imposes pathology on all organs. Simultaneously, severe injury also elicits activation of …

Structural dynamics-driven discovery of anticancer and antimetastatic effects of diltiazem and glibenclamide targeting urokinase receptor

Y Zhou, M Song, D Xie, S Yan, S Yu, S Xie… - Journal of Medicinal …, 2023 - ACS Publications
Diltiazem and glibenclamide are commonly used hypotensive and antidiabetic drugs. This
study reports the discovery of the potential antitumor and antimetastatic effects of these two …

Plasminogen activator inhibitor‐1 regulates macrophage‐dependent postoperative adhesion by enhancing EGF‐HER1 signaling in mice

K Honjo, S Munakata, Y Tashiro, Y Salama… - The FASEB …, 2017 - Wiley Online Library
Adhesive small bowel obstruction remains a common problem for surgeons. After surgery,
platelet aggregation contributes to coagulation cascade and fibrin clot formation. With …